AIM: The aim of this study was to creatively implement a novel chemo-gene-virotherapeutic strategy and further strengthen the antitumor effect in cancer cells by the combined use of ZD55-IL-24 and cisplatin. METHODS: ZD55-IL-24 is an oncolytic adenovirus that harbors interleukin 24 (IL-24), which has a strong antitumor effect and was identified and evaluated by PCR, RT-PCR, and Western blot analysis. Enhancement of cancer cell death using a combination of ZD55-IL-24 and cisplatin was assessed in several cancer cell lines by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and cytopathic effect (CPE) assay. Apoptosis induction by treatment with ZD55-IL-24 and/or cisplatin was detected in BEL7404 and SMMC7721 by morphological evaluation, apoptotic cell staining, and flow cytometry analysis. In addition, negative effects on normal cells were evaluated in the L-02 cell line using the MTT assay, the CPE assay, morphological evaluation, apoptotic cell staining, and flow cytometry analysis. RESULTS: The combination of ZD55-IL-24 and cisplatin, which is superior to ZD55-IL-24, cisplatin, and ZD55-EGFP, as well as ZD55-EGFP plus cisplatin, resulted in a significantly increased effect. Most importantly, conjugation of ZD55-IL-24 with cisplatin had toxic effects equal to that of cisplatin and did not have overlapping toxicities in normal cells. CONCLUSION: This study showed that ZD55-IL-24 conjugated with cisplatin exhibited a remarkably increased cytotoxic and apoptosis-inducing effect in cancer cells and significantly reduced the toxicity in normal cells through the use of a reduced dose.
AIM: The aim of this study was to creatively implement a novel chemo-gene-virotherapeutic strategy and further strengthen the antitumor effect in cancer cells by the combined use of ZD55-IL-24 and cisplatin. METHODS: ZD55-IL-24 is an oncolytic adenovirus that harbors interleukin 24 (IL-24), which has a strong antitumor effect and was identified and evaluated by PCR, RT-PCR, and Western blot analysis. Enhancement of cancer cell death using a combination of ZD55-IL-24 and cisplatin was assessed in several cancer cell lines by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and cytopathic effect (CPE) assay. Apoptosis induction by treatment with ZD55-IL-24 and/or cisplatin was detected in BEL7404 and SMMC7721 by morphological evaluation, apoptotic cell staining, and flow cytometry analysis. In addition, negative effects on normal cells were evaluated in the L-02 cell line using the MTT assay, the CPE assay, morphological evaluation, apoptotic cell staining, and flow cytometry analysis. RESULTS: The combination of ZD55-IL-24 and cisplatin, which is superior to ZD55-IL-24, cisplatin, and ZD55-EGFP, as well as ZD55-EGFP plus cisplatin, resulted in a significantly increased effect. Most importantly, conjugation of ZD55-IL-24 with cisplatin had toxic effects equal to that of cisplatin and did not have overlapping toxicities in normal cells. CONCLUSION: This study showed that ZD55-IL-24 conjugated with cisplatin exhibited a remarkably increased cytotoxic and apoptosis-inducing effect in cancer cells and significantly reduced the toxicity in normal cells through the use of a reduced dose.
Authors: F R Khuri; J Nemunaitis; I Ganly; J Arseneau; I F Tannock; L Romel; M Gore; J Ironside; R H MacDougall; C Heise; B Randlev; A M Gillenwater; P Bruso; S B Kaye; W K Hong; D H Kirn Journal: Nat Med Date: 2000-08 Impact factor: 53.440
Authors: Irina V Lebedeva; Zao-zhung Su; Yonmee Chang; Shinichi Kitada; John C Reed; Paul B Fisher Journal: Oncogene Date: 2002-01-24 Impact factor: 9.867
Authors: E Y Huang; M T Madireddi; R V Gopalkrishnan; M Leszczyniecka; Z Su; I V Lebedeva; D Kang; H Jiang; J J Lin; D Alexandre; Y Chen; N Vozhilla; M X Mei; K A Christiansen; F Sivo; N I Goldstein; A B Mhashilkar; S Chada; E Huberman; S Pestka; P B Fisher Journal: Oncogene Date: 2001-10-25 Impact factor: 9.867
Authors: Paul B Fisher; Rahul V Gopalkrishnan; Sunil Chada; Rajagopal Ramesh; Elizabeth A Grimm; Myrna R Rosenfeld; David T Curiel; Paul Dent Journal: Cancer Biol Ther Date: 2003 Jul-Aug Impact factor: 4.742
Authors: Zi Lai Zhang; Wei Guo Zou; Chun Xia Luo; Bing Hua Li; Jin Hui Wang; Lan Ying Sun; Qi Jun Qian; Xin Yuan Liu Journal: Cell Res Date: 2003-12 Impact factor: 25.617
Authors: R P Morton; F Rugman; E B Dorman; P J Stoney; J A Wilson; M McCormick; A Veevers; P M Stell Journal: Cancer Chemother Pharmacol Date: 1985 Impact factor: 3.333
Authors: Xu Cao; Lei Ding; Zhi-Zhong Xie; Yong Yang; Matthew Whiteman; Philip K Moore; Jin-Song Bian Journal: Antioxid Redox Signal Date: 2018-06-29 Impact factor: 8.401
Authors: Yang Yan; Songyan Li; Tingting Jia; Xiaohui Du; Yingxin Xu; Yunshan Zhao; Li Li; Kai Liang; Wentao Liang; Huiwei Sun; Rong Li Journal: Tumour Biol Date: 2015-01-28
Authors: Mitchell E Menezes; Praveen Bhoopathi; Anjan K Pradhan; Luni Emdad; Swadesh K Das; Chunqing Guo; Xiang-Yang Wang; Devanand Sarkar; Paul B Fisher Journal: Adv Cancer Res Date: 2018-03-02 Impact factor: 6.242
Authors: Mitchell E Menezes; Shilpa Bhatia; Praveen Bhoopathi; Swadesh K Das; Luni Emdad; Santanu Dasgupta; Paul Dent; Xiang-Yang Wang; Devanand Sarkar; Paul B Fisher Journal: Adv Exp Med Biol Date: 2014 Impact factor: 2.622
Authors: Yang Yan; Yingxin Xu; Yunshan Zhao; Li Li; Peiming Sun; Hailiang Liu; Qinghao Fan; Kai Liang; Wentao Liang; Huiwei Sun; Xiaohui Du; Rong Li Journal: Tumour Biol Date: 2013-09-14
Authors: Adly Yacoub; Renyan Liu; Margaret A Park; Hossein A Hamed; Rupesh Dash; Danielle N Schramm; Devanand Sarkar; Igor P Dimitriev; Jessica K Bell; Steven Grant; Nicholas P Farrell; David T Curiel; Paul B Fisher; Paul Dent Journal: Mol Pharmacol Date: 2009-11-12 Impact factor: 4.436